Ozempic and the Vagina: Dryness, Odor and Yeast Infections

No GLP‑1 label lists a vaginal side effect. Ozempic, Wegovy, Mounjaro and Zepbound name no yeast infection, no bacterial vaginosis, no vaginal dryness and no change in odor, and no trial of these drugs has measured any of them.^[1][2] The drug class that does carry a genital yeast-infection warning is a different one: the SGLT2 inhibitors, such as Jardiance and Farxiga, which many people with diabetes take alongside a GLP‑1.^[5] In head-to-head cohorts, GLP‑1 users had fewer vulvovaginal infections than SGLT2 users, not more.^[7][8] What remains are reports to the FDA, a few plausible indirect routes, and the ordinary causes of vaginal symptoms, which are common at any weight.

What the four labels list, and what they leave out

The words vagina, vulva, candida and mycotic appear nowhere in the semaglutide labels^[1][2] or the tirzepatide labels,^[3][4] and none lists a genital reaction of any kind. The common reactions they do list are almost entirely digestive: nausea, diarrhea, vomiting, constipation and abdominal pain lead every list, with fatigue, hair loss and reflux on the weight-loss labels.

The Wegovy urinary-infection line comes from a table of reactions seen in at least 3% of the 133 adolescents on the drug, set against 67 on placebo.^[2] It is a bladder infection, not a vaginal one, and it does not appear among the adult reactions. The Zepbound line is the only dryness of any kind on the four labels, and it refers to the mouth.^[4]

A missing entry is not proof that something never happens. Labels list what showed up more often on the drug than on placebo in trials of a few thousand people, plus selected post-marketing reports. An uncommon effect, or one that people did not think to mention to a trial nurse, could be missed. What the absence does establish is that no vaginal effect was frequent or consistent enough in the trials for the FDA to require it on the label.

The mix-up: SGLT2 drugs do cause genital yeast infections

The warning people half-remember belongs to the SGLT2 inhibitors, a diabetes class sold as Jardiance, Farxiga, Invokana and Steglatro. They lower blood sugar by pushing glucose out in the urine, and their labels tie that extra urinary sugar directly to the infection risk. The Jardiance label puts it plainly:

JARDIANCE increases urinary glucose excretion and increases the risk of genitourinary infections including urinary tract infections and genital mycotic infections in both male and female patients.

— Jardiance (empagliflozin) prescribing information, section 5.3

On that label, genital yeast infections were among the most common reactions in women, and the grouped terms include vulvovaginal candidiasis, vulvitis and bacterial vaginitis.^[5] A network analysis of 764 diabetes trials graded the link between SGLT2 drugs and genital infection as high certainty; it found no such signal for GLP‑1 drugs, whose main harm was digestive.^[6]

This matters because the two classes are often prescribed together, especially for type 2 diabetes with heart or kidney disease. Someone on Ozempic and Farxiga who gets a yeast infection has a well-documented cause in the second drug. How the two interact more broadly is covered in an SGLT2 inhibitor and a GLP-1 together.

What cohort studies found: fewer infections on a GLP-1, not more

Two large studies compared GLP‑1 users directly with SGLT2 users, which is the comparison that answers the question best.

• Denmark, 2025. Among 52,414 adults with type 2 diabetes starting an SGLT2 drug and 27,023 starting a GLP‑1, the one-year risk of a treated genital tract infection was 2.0% on the SGLT2 drug against 0.7% on the GLP‑1, a risk ratio of 2.95. Urinary infections were the same in both groups, about 10%.^[7]
• All of Us, 2026. In 17,267 US adults with type 2 diabetes, people prescribed semaglutide had a lower hazard of a vulvovaginal candidiasis diagnosis than those prescribed an SGLT2 drug (hazard ratio 0.31 in the per-protocol analysis), and a lower hazard of vaginitis and vulvovaginitis (0.46).^[8]

Both are observational and both compare against SGLT2 users, who have a known extra risk, so they do not show that a GLP‑1 lowers yeast infections compared with taking nothing. They do show that GLP‑1 users were not the group with the problem. We found no study that compared vaginal infections on a GLP‑1 against placebo, and none in people without diabetes taking Wegovy or Zepbound for weight.

What people report to the FDA

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Anyone can file one, the drug does not have to be the cause, and nothing tells you how many people took the drug without a problem. A report count is a signal to look at, not a rate and not proof of harm.^[9]

Two details stand out. Of the 121 semaglutide reports, 36 also listed an SGLT2 drug, so close to a third involved the medicine with the known risk. And the specific complaints people search for are rare in the reports: vaginal dryness appears in 10 semaglutide and 6 tirzepatide reports, and vaginal odor in 3 and 5.^[9] Many tirzepatide reports come from consumers rather than clinicians, which changes what gets reported and how; one analysis of FDA reports on gynecological bleeding found 94.6% of tirzepatide reports came from consumers against 53.4% for semaglutide.^[20]

Dryness: what could plausibly be going on

No study has measured vaginal dryness on a GLP‑1. The routes below are possibilities that fit what is known about the drugs and about vaginal health. None has been shown to cause dryness in people taking these medicines.

• Fluid loss. All four labels say vomiting, diarrhea and nausea can lead to dehydration, and tell prescribers to advise patients to avoid fluid depletion.^[1][3] Whether ordinary dehydration reduces vaginal lubrication has not been studied in this setting. It is an inference, not a finding.
• Menopause. Many people starting these drugs are in their 40s and 50s. Genitourinary syndrome of menopause is defined by symptoms that follow falling estrogen and androgen levels in the genital tract, and dryness is central to it.^[14] A GLP‑1 started during perimenopause can coincide with dryness that the hormonal change alone would explain. What is and is not known about these drugs after menopause is in GLP-1 drugs after menopause.
• Sexual arousal and desire. Two 2026 reviews note case reports and animal data suggesting GLP‑1 drugs might dampen desire, while calling the human evidence limited and mixed.^[15][16] Lower arousal means less lubrication, so this route is possible. It has not been measured.
• Hormone changes from fat loss. The authors of one case report proposed that rapid fat loss on semaglutide might alter how estrogen is handled in the body. They offered it as a hypothesis to explain bleeding, not dryness, and did not measure it.^[17]

Dryness that comes with menopause has effective treatment. A 2025 urology and gynecology guideline found that low-dose vaginal estrogen has the strongest evidence base, alongside nonhormonal moisturizers and lubricants.^[14] Nothing about taking a GLP‑1 rules that treatment out.

Odor: usually an infection, not the drug

A new vaginal odor is most often a sign of a common infection, and the CDC guidance is clear that symptoms alone are not enough to tell which one. Bacterial vaginosis is the most common cause of vaginal discharge worldwide, and a fishy odor is one of its diagnostic signs. Trichomoniasis, a sexually transmitted infection, can cause discharge described as malodorous or yellow-green. Yeast infections typically cause itching, soreness, pain with sex or urination, and abnormal discharge.^[10]

We found no study linking any GLP‑1 to bacterial vaginosis, and the FDA receives few such reports: six for semaglutide and five for tirzepatide.^[9] Social posts blame diet changes, ketosis or sweat for odor on these drugs. None of those has been studied in GLP‑1 users. Changes to the skin and fat of the vulva itself are a separate topic, covered on the companion page about the vulva.

Yeast infections and blood sugar

Yeast infections are common in everyone. A CDC-run survey found that 5.2% of US women had a clinician-diagnosed yeast infection in the previous year and 53% had one at some point in their lives.^[11] Diabetes nearly tripled the odds of a recent infection in that survey, and the CDC classes infections in women with diabetes as complicated, needing a different approach to treatment.^[11][10] A Swedish study of 1.8 million women found that a yeast infection often preceded a diabetes diagnosis, especially after age 55.^[12]

That points in a useful direction. High blood sugar favors yeast; diabetes appears in every list of risk factors, alongside hormonal changes, antibiotics and immune problems.^[13] A GLP‑1 lowers blood sugar. It is reasonable to expect that better glucose control would, if anything, reduce yeast risk over time, though no trial has tested it. Two practical exceptions: a course of antibiotics for something else, and starting an SGLT2 drug, both raise the risk regardless of the GLP‑1.

Repeated yeast infections are worth reporting even if they seem minor. The CDC guidance says anyone whose symptoms persist after an over-the-counter treatment, or come back within two months, should be examined and tested.^[10] For someone who has not been tested for diabetes, recurring yeast infections are a reason to ask for a blood sugar check.^[12]

Bleeding is a separate signal

Some searches for vaginal side effects are really about bleeding. Here there is a little more to report, all of it from case reports and FDA reporting data. A 2026 analysis of FDA reports in women aged 12 to 55 found semaglutide reported disproportionately with heavy menstrual bleeding, bleeding between periods and infrequent periods, and tirzepatide with bleeding between periods and clots.^[19] Disproportionate reporting is a signal, not a measured rate. Two case reports describe heavy vaginal bleeding that started soon after a GLP‑1 was begun and stopped after it was withdrawn: one on semaglutide in a postmenopausal woman, one on dulaglutide in a perimenopausal woman.^[17][18]

Bleeding after menopause needs an exam regardless of what medicine is involved; the semaglutide case report itself stresses ruling out cancer first.^[17] On the pill, changes in bleeding pattern have another possible explanation: Mounjaro and Zepbound ask pill users to rely on a backup or a non-pill method around the first dose and every dose step,^[3][4] which is covered in GLP-1 drugs and hormonal birth control.

When to see a clinician

The CDC notes that most women will have a vaginal infection at some point, and that a history alone often leads to the wrong treatment.^[10] Book an exam, rather than self-treating, for any of these:

• A first-ever episode of itching, burning or unusual discharge, or a new fishy or strong odor.
• Symptoms that persist after an over-the-counter yeast treatment, or return within two months.
• Discharge that is green, yellow or frothy, or symptoms after a new sexual partner.
• Pain during sex or urination that is new.
• Any bleeding after menopause, or heavy or prolonged bleeding between periods.

It also helps to bring a full medication list. An SGLT2 drug, a recent antibiotic, a steroid or a change in birth control can each explain symptoms that look like a GLP‑1 side effect. The wider list of what interacts with these drugs is in GLP-1 drugs and your other medications, and low blood sugar risk, which matters if diabetes treatment is being adjusted, is in GLP-1 drugs and low blood sugar.